MET097 for Obesity
(VESPER-4 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive once-weekly injectable MET097 or placebo for 64 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- MET097
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Placebo Group
Participants will receive MET097 administered subcutaneously
Participants will receive MET097 administered subcutaneously
Participants will receive MET097 administered subcutaneously
Once-weekly placebo administered via subcutaneous injection
Find a Clinic Near You
Who Is Running the Clinical Trial?
Metsera
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.